CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Marinomed Biotech AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Marinomed Biotech AG
Hovengasse 25
Phone: +43 226290300p:+43 226290300 KORNEUBURG, 2100  Austria Ticker: MARIMARI
Business Summary
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board SimonNebel 6/2/2017 6/2/2017
Chairman of the Executive Board, Chief Executive Officer AndreasGrassauer 53 1/1/2006 1/1/2006
Independent Deputy Chairman of the Supervisory Board UteLassnig 52 1/1/2021 6/2/2017
4 additional Officers and Directors records available in full report.

Business Names
Business Name
MARI
MBG

General Information
Number of Employees: 47 (As of 12/31/2023)
Outstanding Shares: 1,694,583 (As of 10/10/2024)
Stock Exchange: WBAG
Fax Number: +43 226290300500


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024